Lameness Repair Company

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, January 16, 2018 /EINPresswire.com/ — PetVivo Holdings, Inc. Adds Mr. Thomas Yezzi to Advisory Board.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

PRESS RELEASE

PETVIVO HOLDINGS, INC. ADDS MR. THOMAS YEZZI TO ADVISORY BOARD

Minneapolis, MN Jan. 16, 2018 PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company, is excited with the addition of Mr. Thomas Yezzi to the Advisory Board. Mr. Yezzi has over 20 years’ experience in the food ingredient and biotech industry, and has developed a broad network of venture partners, investors, and research scientists. His entrepreneurial focus has been on start-up and early stage companies. He is currently the President and Founder of Nu-Tek Products, a business incubator for wellness foods and life sciences ventures. He also serves as the President of two portfolio companies, Nu-Tek BioSciences and Nu-Tek Fibers.
Mr. Yezzi was a co-founder of Nu-Tek Salt. He served as President through the start-up and commercialization phases of the Company. His efforts contributed to sizeable funding from large VC’s such as Khosla Ventures.
Mr. Yezzi has also held senior management positions in Operations, Business Development, and Process Development. He was the Vice President of Operations at Protient, Inc., a value-added food ingredient company focusing on the fractionation and purification of milk, whey, and soy proteins. He helped build Protient into a successful food ingredient business using venture capital seed/start-up money. The company was sold in 2005 to one of Europe’s largest food companies. From 1993 to 2000, Mr. Yezzi was Director of Process and Product Development at Northern Food & Dairy, Inc., A SunOpta Company. He managed and generated new business in the nutraceutical, soy, and dairy industries. Tom successfully led many projects from the lab into commercial production. The company focused on custom/toll processing for large food companies such as Novartis, Dupont, Quaker Oats, Taiyo, White Wave, and Westbrae.
Mr. Yezzi holds Bachelor’s and Master’s degrees in Food Science from the University of Minnesota. His focus and research were in the areas of food and industrial microbiology.
“It is not only exciting but comfortably familiar having Mr. Yezzi as part of the team after having worked with him before. His skill sets are exceptional in the areas of manufacturing and scaling up. His background in microbiology and the work I have seen him previously involved with, adds greatly to the team that is setting up our labs and manufacturing capabilities.” Stated Wes Hayne, CEO of PetVivo Holdings, Inc.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 952-405-6216
Direct: (763) 443-7272

Wes Hayne
Petvivo Holdings, Inc.
952-405-6216
email us here

PetVivo Holdings, Inc. Airs on Fox Business Network

MINNEAPOLIS, Jan. 04, 2018 (GLOBE NEWSWIRE) — (OTCMARKETS:PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is happy to announce that the interview recently aired on the FOX Business Network, Saturday, December  23, 2017, at 3:00 PM Eastern/12:00 AM Pacific, on “New to the Street” is now available for viewing on demand on our company website www.petvivo.com and on the “New to the Street” YouTube channel  for those that may have missed the broadcast.

John Lai, President of Petvivo Holdings Inc. stated, “… that with the forthcoming launch of the Kush product and the impact that we are hoping for, it will bring a new quality of life to those dogs and horses we love. We are expecting a warm welcome with our product to the delivery of healthcare to the veterinary world. We felt it was important to bring it to the public at large and that television would be one of the best mediums to get the message out there. Therefore, we are proud to make available the interview on our website and through the New to the Street” YouTube channel.

FMW Media Works Corp. (“New To The Street“) is a leading provider of business profiles and special corporate programming. FMW Media Works produces “New to the Street” which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. “New to the Street” airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations. Visit www.NewToTheStreet.com.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: 952-405-6216

Direct: (763) 443-7272

Source: PetVivo Holdings Inc.

PetVivo Hires Randy Wenthold to Replace David Masters as Chief Technical Officer

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

PETVIVO HIRES MR. RANDY WENTHOLD AS CSO

MINNEAPOLIS, Dec. 28, 2017 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCMARKETS:PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people has brought on Mr. Randy Wenthold into the position of Chief Science Officer. Mr. Wenthold will take over some of the responsibilities that Dr. Masters previously had on a day to day basis regarding product development, commercial production, and regulatory issues.

Dr. Masters has decided to resign from all his corporate positions with exception that he has chosen to remain as an active member of the Board of Directors of PetVivo Holdings, Inc.

“Now that the company is approaching commercial production, the addition of Mr. Wenthold into the position of Science Officer makes for a perfect fit. His experience in lab development and regulatory experience will allow us to address not only the initial production as scheduled, but also expand production capabilities given the success we expect with the launch of our first product,” stated PetVivo’s CEO, Wes Hayne.

Mr. Wenthold has been involved with medical devices from a development, manufacturing, and division management role for over 25 years. He was responsible for the development and market launch of the Renaflo acute renal failure family of filter products and Hemocor cardiosurgery fluid removal family of products (including the pediatric Junior device). Additional products he has developed are the Fibercor family of industrial filters, Vital Therapies ELAD and UFG filters, fiber used in an I-Flo drug delivery catheter, fiber or membranes used for implantable fiber devices and military water purification. Randy is named as the inventor of 3 patents and two provisional patents.

From 2012 until present he has been a medical device consultant specializing in the development of medical device products supporting cardiosurgery, sepsis and liver failure.

Mr. Wenthold stated, “I am excited to take on the role with Petvivo and build upon the previous contributions from Dr. Masters. I’m confident my previous experiences and expertise combined with those of the management team will contribute to the success planned for the company.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCMARKETS:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

Source: PetVivo Holdings Inc.

“New to the Street” Proudly Announces its Upcoming Telecast on FOX Business, Saturday, December 23, 2017 @ 3PM EST

Global Capital Network Investor Roadshow Begins in La Jolla

Source: Global Capital Network

LA JOLLA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) — Global Capital Network (GCN) will conclude its year end work with emerging growth companies with it’s winter investor roadshow series in California.  The companies will present from December 5th to December 8th in La Jolla, Orange County, Santa Monica and San Francisco.  Companies include exemplary private start up and public emerging growth opportunities such as Herohl (www.herohl.com) and Petvivo (OTC:PETV).

Herohl is a nutritional supplement designed to combat bone and joint disease.  The CEO, Sabine Ohly, says of Herohl’s mission, “Over 50 million people are affected by arthritis in the United States and their biggest challenge is how to live a normal life and stay motivated while suffering from chronic pain, fatigue, physical and functional limitations as well as other consequences from chronic joint pain. Herohl’s goal is to provide them with an alternative, healthier and more affordable solution to painkillers with this new revolutionary dietary supplement.”

John Lai, founder of the Petvivo (PETV), an award winning osteoarthritis treatment for pets, notes of Petvivo’s growth, “Petvivo has made tremendous progress with additions to the board of directors, advisory board and the changes in management that have taken place in the last four months. First time commercial production is scheduled to start in December (2017), with sales and distribution underway to support the launch of our first product. Thus we will start concentrating on a goal of cash flow. Kush, our first product is aimed at the companion animal sector.”

Global Capital Network looks to host capacity audiences in each of its four locations.  The best performing part of the markets right now are micro-cap companies- the smallest of the small stocks. “You have a confluence of the reflation trade, rising rates, and the tax cut trade,” Martin Small, U.S. head of iShares at BlackRock has said, “All these things are positive for small- and micro-cap stocks.”  GCN looks to continue its work since 2010, working with hundreds of companies in markets across the US.

DISCLAIMER: Global Capital Network assists small to mid-sized emerging-growth public and private companies in gaining exposure and creating funding awareness. GCN conferences and investor roadshows are intended to provide FINRA broker/dealers, investment bankers, investment advisors, analysts, financial managers, fund managers, institutions, media and accredited investors with a forum for networking and communication.

Patrick A. Howell, phowell@sandiegoinvestmentconference.com, (949)813-1756 (c)

PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals

Petvivo Holdings Inc. (OTCMKTS:PETV)

MINNEAPOLIS, MINNESOTA, USA, November 21, 2017 /EINPresswire.com/ — Press Release PetVivo Receives Uppie Award for “Best Medical Technologies for Human or Animals”
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
Created:
Tuesday, 11-21-2017
PRESS RELEASE
PETVIVO RECIEVES UPPIE AWARD FOR “BEST MEDICAL TECHNOLOGIES FOR HUMAN OR ANIMALS”.
PetVivo Holdings, Inc. OTCPINK: PETV (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce receiving the Uppie Award for “Best Medical Technologies for Human or Animals”, category. Prior to the award announcements, Petvivo was nominated for three categories; Best CEO, Best Medical Technologies for Humans or Animals and Best Scientific Medical Products.
“Petvivo continues to move forward. Our product is attracting the attention from both the investment and medical communities. The public is growing more aware of the company as we near our date for commercial production. We want to thank Uptick Newswire and the Uppie Awards for their recognition of our progress”, said Mr. Wes Hayne, CEO of Petvivo Holdings, Inc.
The Uppie Awards are produced by Uptick Newswire, an Investor Relations firm that provides services to publicly-traded micro-cap and nano-tech companies on the OTC, NYSE and CSE exchanges. The awards ceremony took place November 3rd, 2017 at the Flamingo Hotel in Las Vegas, Nevada, and was attended by micro-cap investors, boutique hedge-fund managers as well as local and national media outlets.
Mr. John Lai, the President of Petvivo Holdings, accepted the award, stating, “I want to thank the Academy…. opps, wrong city and speech (laughing). Seriously, I want to thank the Uppie Awards on behalf of the Company. It is an honor to accept this award. We look forward to next year.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

Press Release PetVivo Adds Mr. David Merrill to the Board of Directors

Eden Prairie, MN, Nov. 09, 2017 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCMARKETS: PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Mr. David Merrill has joined the Company’s Board of Directors.

Mr. Merrill is an accomplished Senior Executive in the Medical Device Industry. He is currently the CEO of the Merrill Family Enterprises, LLC (FME) which in different capacities gets directly involvedwith Medical Device companies.

: “I’m honored to join the PetVivo Holdings team. I evaluated the opportunity based upon the team’s leadership, fiscal responsibility, patent portfolio (existing and in process) and the science. Does the Science offer positive patient, medical professional and economic outcomes? PetVivo surpassed my expectations”

Mr. Merrill started his lengthy Medical Device career at Medtronic in 1973 selling implantable cardiac devices. After being inducted into the prestigious Medtronic’s President’s Club for his achievements, Merrill career expanded to District Manager then to Director, Sales Development, and Support in 1982. At that time, he moved to St. Jude Medical as Senior Director of their Southwest Region overseeing Direct and Independent sales representatives in 10 states. Roughly ten years from joining St. Jude he returned to Medtronic’s to be Vice President, Cardiac Rhythm Management, Asia-Pacific. He relocated to Hong Kong working internationally until his early retirement (30 Years) from Medtronic

After finding his retirement highly over rated he joined I-Flow as VP of International. During his time with I-Flow he negotiated distribution agreements throughout the UK, Scandinavia, Korea, Japan, Mexico, Brazil, Turkey, India, China etc., increased annual revenues and gross margins. The company was sold to Kimberly-Clark.In addition, Mr. Merrill has negotiated agreements with such medical giants as B. Braum, Fresenius-Kabi and Terumo.

“I first met David in High School some 50+ years ago in St. Paul, Minnesota. We lost track of each other from time to time, but reconnected a couple of months ago as we discussed an idea that David called me about regarding our product. One thing always leads to another. I am excited that after some 14,000,000 miles and at one time or another having worked in 53 countries David has decided to share his expertise in medical products and international distribution with PetVivo. In addition to the excitement, I know it will be fun having David around.” Stated Wes Hayne, PetVivo’s CEO.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

Press Release PetVivo Holding, Inc. Reports Progress to Shareholders

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

 

Created:

Tuesday, 10-17-2017

PRESS RELEASE

 

PetVivo HOldings Provides Shareholder Update

 

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to provide an update to our shareholders.

 

Information and skilled execution has always led the way to success. It is important to us, the management team of your company, be committed to informing all shareholders of the progress that has been made and is currently underway. Several major steps forward have been taken in the last few months, and there is potentially more to come in the next few.

 

First, I will address the management changes and additions. I accepted the position of CEO and Board Member in June. At the end of August, Cynthia Jenkins joined the company as CFO. The month of September saw the addition of David Deming and Peter Vezmar to the Board of Directors. October solidified the addition of Robin Young and Michael Haider to the Advisory Board. All of the business biographies of these individuals are posted on our website (www.petvivo.com) .

 

Second, as a reporting company, PetVivo has continued the effort to catch up on delinquent filings. It is projected that the final filing to bring the company current with the Securities and Exchange Commission will be submitted in early November. Once current our financial results will be available at most financial web portals that provide financial data.

 

PetVivo has a new home that is in final construction in Edina, Minnesota. Corporate offices, Research and Commercial production facilities will be ready for full operation on December 1st. The first commercial runs of “Kush” will be supporting the sales and marketing roll out scheduled to commence at the same time. We are currently assembling the sales and distribution team that will introduce our first product.

 

Financial support for these activities comes from the completion and oversold round of $525,000 of financing, which ended only last week. The funding is expected to complete the construction and fund the early stages of market and sales.

 

The stock (PETV) has experienced considerable appreciation over the last six months as confidence by investors has grown with the company achieving specific benchmarks. The practice of goal setting, short term and long term has become the norm among the management of your company. We continue to push forward each and every day to make out products a primary component in the canine, equine and eventually human solutions for the future.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: (612) 296-7305

Direct: (763) 443-7272

 

 

 

 

 

 

 

 

 

 

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts

Press Release PetVivo Expands Advisory Board With Stem Cell and Orthopedics Experts
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )

Created:
Monday, 10-09-2017
PRESS RELEASE

PETVIVO ADDS ROBIN YOUNG AND MICHAEL HAIDER TO ADVISORY BOARD

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to announce that Robin R. Young and Michael P. Haider have joined the Company’s Advisory Board.

Mr. Young is currently Chief Executive Officer of RRY Publications LLC and PearlDiver Technologies, Inc. RRY Publications is the publisher of Orthopedics This Week and organizer of educational seminars on such topics as Stem Cell Therapies, Clinical Research Issues and New Healthcare Technologies. RRY Publications reaches approximately 200,000 healthcare professionals monthly. PearlDiver is a data mining company which is used by both academic and corporate researchers to conduct research. PearlDiver has been cited in more than 75 peer reviewed journal studies. Previously, Mr. Young spent twenty-five years as a medical technology analyst with such firms as Piper Jaffray, Stephens, Inc. and HealthPoint Capital.

Mr. Young has been a podium speaker at the Foundation for Orthopedic Research, International Society for Advancement Spine Surgery, Laser Spine Institute, Johnson & Johnson Global R&D Congress, The Vatican and the Cedars Sinai Surgeon Conference. His subject topics have included Spine Surgery, Future of Orthopedics, Stem Cells, Regenerative Medicine and Allograft Surgical Products to name a few.

“PetVivo’s developing portfolio of advance biologic therapies is very exciting. I’m looking forward to contributing to the company’s development and success. The pace of medical innovation is accelerating and companies like PetVivo play a critical role in moving these important new technologies from the lab to the practitioner.”

Mr. Haider has over 40 years of medical business, finance and management experience, currently serving as the Co-Founder and CEO of CytoMedical Design Group LLC, a blood based stem cell research company. He previously served as the President and CEO of BioE LLC and BioE, Inc; President/Owner of Kodiak Restoration, a dental and medical equipment service company; Co-founder and President of PulseTrend, Inc., an ambulatory blood pressure device manufacturer; and as Vice President and Chief Financial Officer of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Mr. Haider held a variety of corporate finance positions at Medtronic, Inc., a leading provider of medical devices.

Mr. Haider and the companies he has led have been named one of the Twin Cities-based Finance and Commerce’s “Innovators of The Year”, received the Minnesota Tekne Award in the Emerging Biotechnology category and a Twin Cities Business, Biosciences Success Story. Since 2009, he has served as a member of National Marrow Foundation (“Be the Match”), New Technology Council and for the past decade he has been an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.

“I am pleased for the opportunity to contribute my business and technical experience to help the commercial success of PetVivo’s exciting technologies and new Kush product line. I am looking forward to working with the terrific team Wes and John are putting together, stated Mr. Haider.

“I have known Robin Young for over three generations. During that time, I have always been fascinated with his achievements. I am looking forward to his continued support and contributions. Mike Haider and I ran into each other quite by accident several years ago in London, England. It was only after conversing a while did we discover that we were both from Minnesota. Mike and Robin have decades of experience in regenerative medicine, more specifically stem cells. It is a privilege to have them working with us,” Said PetVivo’s CEO, Wes Hayne.

About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: (612) 296-7305
Direct: (763) 443-7272

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

FMW Media Works Corp.’s “New To The Street” Business TV On October 26, 2017, Films Exciting New Line-up – PetVivo Holdings, Inc (PETV), Premier Biomedical, Inc. (BIEI) and Strikeforce Technologies, Inc.(SFOR)

 

GlobeNewswireOctober 3, 2017

NEW YORK, Oct. 03, 2017 (GLOBE NEWSWIRE) — “New To The Street,” a business television show, announces the addition of three exciting new clients to its list of profiled companies, PetVivo Holdings Inc. (PETV), Premier Biomedical, Inc. (BIEI), and Strikeforce Technologies, Inc. (SFOR); filming at show’s NYC broadcasting studios, Thursday, October 26, 2017.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/56f7f35b-3cf1-4308-b11b-2c61de050a7e

Mr. John Lai, President, PetVivo Holdings Inc., a company which developed an exciting technology to combat osteoarthritis in the canine and equine population. John plans to discuss PetVivo Holdings, Inc.’s technology, strategy and mission to deliver treatment for osteoarthritis, improving the lives of the many four- legged friends that families love.

Mr. Lai states, “I’m looking forward to discuss on ‘New To The Street’ how PetVivo’s disruptive technology can revolutionize the treatment and care of osteoarthritis in dogs and horses.  And, I’m excited for PETV to launch commercially its ‘Kush’ product and enter a $3 Billion plus market with this innovative technology.”

Also in the studio, William A Hartman, CEO of Premier Biomedical Inc. to discuss the company’s fight against pain with their phytocannabinoids products. He plans to discuss their recently launched website www.painreliefmeds.com, and how people with pain can find out about their phytocannabinoids products and find relief.

With the recent increases in cyber “hackings,” Mark Kay, CEO of Strikeforce Technologies, Inc. discusses his company’s place in the fight against cyber theft and data breaches. Strikeforce’s designed a suite of services to provide anonymity of your personal and financial information – ProtectID, GuardedID, and Mobiletrust products protect against thieves and hackers with the intent to steal personal information.

Viewers, please look out for the entire guest line-up the week of October 26, 2017. See which Companies profiled on “New To The Street’s” December Broadcast on Fox Business Network TV.  Watch for more news on show’s guests, Agritek Holdings, Inc. (AGTK), Financial Gravity (FGCO), DIBcoin cryptocurrency, Vystar Corp.(OTCPINK:VYST), Genoil, Inc.(GNOLF), MoneyOnMobile, Inc. (MOMT) and Kimberly Parry Organics Company (KPOC).

FMW Media Works Corp. (“New To The Street“) is a leading provider of business profiles and special corporate programming. FMW Media Works produces “New To The Street” which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. “New To The Street” airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations- www.NewToTheStreet.com.

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. This press release should be considered in light of all filings of the Company that is contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

Contact Information:

For “NEW TO THE STREET”
Adam Becker
(631) 465-0284
Adam.becker@newtothestreet.com

PetVivo Holdings
Wes Hayne, CEO
(612) 296-7305
info@petvivo.com
www.petvivo.com

Premier Biomedical Inc.
William A Hartman, CEO
(724) 633-7033
w.hartman@premierbiomedical.com
premierbiomedical.com

 

 

Real Time Web Analytics